Baseline characteristics

Bortezomib, Doxorubicin Hydrochloride Liposome, and Thalidomide as First-line Therapy in Treating Patients With Previously Untreated Stage I, II, or III Multiple Myeloma · Source last updated 2017-02-23

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

denoms

1. counts

   1. group Id

      BG000

      value

      40

   units

   Participants

groups

1. id

   BG000

   title

   VDT: VELCADE, Doxil and Low-dose Thalidomide

measures

1. classes

   1. categories

      1. measurements

         1. group Id

            BG000

            spread

            9.34

            value

            60.13

   dispersion Type

   STANDARD_DEVIATION

   param Type

   MEAN

   title

   Age, Continuous

   unit Of Measure

   years

2. classes

   1. categories

      1. measurements

         1. group Id

            BG000

            value

            14

         title

         Female

      2. measurements

         1. group Id

            BG000

            value

            26

         title

         Male

   param Type

   COUNT_OF_PARTICIPANTS

   title

   Gender

   unit Of Measure

   Participants

population Description

Evaluable Patients

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice